IPSC
Century Therapeutics, Inc. NASDAQ Listed Jun 18, 2021$2.31
Mkt Cap $200.0M
52w Low $0.43
72.0% of range
52w High $3.04
50d MA $2.33
200d MA $1.26
P/E (TTM)
-21.0x
EV/EBITDA
-35.0x
P/B
1.3x
Debt/Equity
0.3x
ROE
-6.0%
P/FCF
-0.8x
RSI (14)
—
ATR (14)
—
Beta
1.67
50d MA
$2.33
200d MA
$1.26
Avg Volume
1.3M
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
3675 Market Street · Philadelphia, PA 19104 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | AMC | -0.28 | -0.25 | +10.7% | 2.50 | -0.8% | -6.4% | +3.8% | -5.8% | +0.4% | +8.3% | — |
| Nov 13, 2025 | AMC | -0.39 | -0.32 | +17.9% | 0.46 | +3.3% | +1.7% | +1.7% | +2.0% | +5.5% | -5.1% | — |
| Aug 14, 2025 | AMC | -0.38 | -0.38 | +0.0% | 0.55 | +4.2% | +2.1% | +2.2% | -4.2% | -0.9% | -0.7% | — |
| May 15, 2025 | AMC | -0.31 | 0.89 | +387.1% | 0.52 | +0.0% | +8.2% | -1.0% | +8.2% | -3.4% | -0.9% | — |
| Mar 19, 2025 | AMC | -0.45 | -0.43 | +4.4% | 0.58 | -1.5% | -5.7% | +0.9% | +5.2% | -5.0% | +0.2% | — |
| Nov 5, 2024 | AMC | -0.46 | -0.37 | +19.6% | 1.33 | +9.0% | +4.5% | +5.0% | -1.4% | +2.1% | -4.1% | — |
| Aug 8, 2024 | AMC | -0.50 | -0.38 | +24.0% | 1.80 | +2.8% | -4.4% | -3.5% | -0.6% | -5.5% | +6.4% | — |
| May 9, 2024 | AMC | -0.50 | -0.45 | +10.0% | 3.04 | +0.3% | +3.0% | -4.2% | +5.0% | -1.9% | +1.3% | — |
| Mar 14, 2024 | AMC | -0.56 | -0.49 | +12.5% | 4.51 | +6.7% | +10.9% | -5.0% | +1.1% | +4.4% | -4.6% | — |
| Nov 9, 2023 | AMC | -0.53 | -0.55 | -3.8% | 1.39 | +4.3% | -7.2% | -0.8% | +2.3% | -0.8% | +2.3% | — |
| Aug 9, 2023 | AMC | -0.54 | -0.56 | -3.7% | 2.85 | +0.7% | -4.9% | +3.3% | -1.1% | -1.1% | -1.1% | — |
| May 11, 2023 | AMC | -0.53 | -0.53 | +0.0% | 3.37 | +1.5% | -2.7% | +0.9% | -3.9% | -2.5% | +2.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.34 | $2.45 | +4.7% | -1.7% | +6.1% | -7.4% | -1.8% | +1.4% |
| Jan 20 | Piper Sandler | Maintains | Overweight → Overweight | — | $2.17 | $2.13 | -1.8% | -11.5% | +6.2% | +13.2% | +4.8% | +6.6% |
| Nov 17 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $0.47 | $0.47 | -0.2% | +1.7% | +2.0% | +5.5% | -5.1% | -0.1% |
| May 16 | Chardan Capital | Maintains | Buy → Buy | — | $0.52 | $0.52 | +0.0% | +8.2% | -1.0% | +8.2% | -3.4% | -0.9% |
| Apr 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.47 | $0.46 | -2.1% | -2.3% | -4.3% | -6.1% | -5.6% | +7.6% |
| Mar 28 | Guggenheim | Maintains | Buy → Buy | — | $0.55 | $0.55 | +0.2% | -6.5% | -7.2% | -5.1% | +4.0% | -2.3% |
| Mar 24 | Chardan Capital | Maintains | Buy → Buy | — | $0.56 | $0.57 | +2.7% | +5.2% | -5.0% | +0.2% | -1.4% | -6.5% |
| Mar 21 | Guggenheim | Maintains | Buy → Buy | — | $0.55 | $0.55 | +0.2% | +0.9% | +5.2% | -5.0% | +0.2% | -1.4% |
| Mar 20 | Piper Sandler | Maintains | Overweight → Overweight | — | $0.58 | $0.57 | -1.5% | -5.7% | +0.9% | +5.2% | -5.0% | +0.2% |
| Jan 22 | Guggenheim | Maintains | Buy → Buy | — | $0.90 | $0.93 | +3.7% | -0.7% | +2.1% | -1.1% | -2.8% | -3.4% |
| Jan 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.90 | $0.93 | +3.7% | -0.7% | +2.1% | -1.1% | -2.8% | -3.4% |
| Dec 30 | Piper Sandler | Maintains | Overweight → Overweight | — | $1.04 | $1.05 | +1.0% | -3.8% | +1.0% | +3.0% | +6.7% | -5.4% |
| Nov 7 | Chardan Capital | Maintains | Buy → Buy | — | $1.39 | $1.38 | -0.7% | +5.0% | -1.4% | +2.1% | -4.1% | -5.7% |
| Nov 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.33 | $1.45 | +9.0% | +4.5% | +5.0% | -1.4% | +2.1% | -4.1% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.56 | $1.63 | +4.5% | +6.4% | -3.0% | +6.2% | -1.8% | +6.5% |
| Jun 17 | Piper Sandler | Maintains | Overweight → Overweight | — | $3.13 | $3.20 | +2.2% | +0.6% | -5.7% | -9.4% | +6.3% | -6.3% |
| Jun 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.98 | $2.95 | -1.0% | +2.3% | -1.6% | +0.7% | -2.6% | +13.9% |
| May 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.04 | $3.05 | +0.3% | +3.0% | -4.2% | +5.0% | -1.9% | +1.3% |
| Apr 12 | Piper Sandler | Maintains | Overweight → Overweight | — | $4.05 | $4.01 | -1.0% | -3.5% | -6.1% | -14.4% | -9.6% | +4.9% |
| Mar 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.51 | $4.81 | +6.7% | +10.9% | -5.0% | +1.1% | +4.4% | -4.6% |
| Mar 15 | Canaccord Genuity | Maintains | Buy → Buy | — | $4.51 | $4.81 | +6.7% | +10.9% | -5.0% | +1.1% | +4.4% | -4.6% |
| Dec 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.15 | $2.19 | +1.9% | +8.4% | +2.1% | -1.3% | +11.9% | +1.1% |
| Aug 28 | JP Morgan | Downgrade | Overweight → Neutral | — | $2.39 | $2.53 | +5.9% | +5.0% | -3.6% | +0.8% | +1.6% | -0.4% |
| Aug 10 | Piper Sandler | Maintains | Overweight → Overweight | — | $2.85 | $2.87 | +0.7% | -4.9% | +3.3% | -1.1% | -1.1% | -1.1% |
| Aug 10 | Chardan Capital | Maintains | Buy → Buy | — | $2.85 | $2.87 | +0.7% | -4.9% | +3.3% | -1.1% | -1.1% | -1.1% |
| Aug 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.85 | $2.87 | +0.7% | -4.9% | +3.3% | -1.1% | -1.1% | -1.1% |
| Aug 10 | EF Hutton | Maintains | Buy → Buy | — | $2.85 | $2.87 | +0.7% | -4.9% | +3.3% | -1.1% | -1.1% | -1.1% |
| May 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.37 | $3.42 | +1.5% | -2.7% | +0.9% | -3.9% | -2.5% | +2.9% |
| Apr 17 | EF Hutton | Maintains | Buy → Buy | — | $3.11 | $3.20 | +2.9% | +1.3% | -2.2% | +2.3% | -1.6% | -1.9% |
| Mar 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.98 | $4.00 | +0.5% | -3.0% | +2.1% | -4.6% | -5.3% | -2.0% |
| Jan 6 | Piper Sandler | Maintains | Overweight → Overweight | — | $4.84 | $5.01 | +3.5% | +1.7% | -2.8% | -2.3% | -1.7% | +4.6% |
| Jan 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.84 | $5.01 | +3.5% | +1.7% | -2.8% | -2.3% | -1.7% | +4.6% |
| Jan 6 | EF Hutton | Maintains | Buy → Buy | — | $4.84 | $5.01 | +3.5% | +1.7% | -2.8% | -2.3% | -1.7% | +4.6% |
| Jan 6 | SVB Leerink | Maintains | Outperform → Outperform | — | $4.84 | $5.01 | +3.5% | +1.7% | -2.8% | -2.3% | -1.7% | +4.6% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.00 | $10.85 | -1.4% | -2.3% | -6.0% | +0.9% | +4.7% | +2.5% |
| May 17 | Piper Sandler | Maintains | Overweight → Overweight | — | $8.86 | $9.07 | +2.4% | +2.5% | -3.2% | -4.4% | +1.3% | +4.1% |
| Apr 29 | SVB Leerink | Maintains | Outperform → Outperform | — | $12.03 | $11.77 | -2.2% | -0.1% | +2.4% | +0.6% | +0.1% | -14.0% |
| Nov 19 | SVB Leerink | Maintains | Outperform → Outperform | — | $20.95 | $20.79 | -0.8% | -1.6% | -17.6% | +4.2% | +1.4% | -4.2% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 4, 2026 | Carr Douglas | SVP Finance & Operations | Sell | 264 | $2.34 | $618 | 506,997 | -1.28% | — |
8-K · 2.02
!! High
Century Therapeutics, Inc. -- 8-K 2.02: Earnings Results
May 13
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Innocence is activating its shelf registration to conduct an at-the-market offering, potentially diluting existing shareholders while raising capital for operations or strategic purposes.
Mar 26
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Century Therapeutics disclosed material information via press release and investor presentation on March 12, 2026, which investors should review for potential operational updates, clinical trial results, or strategic announcements affecting stock valuation.
Mar 12
Data updated apr 25, 2026 4:07pm
· Source: massive.com